NICE gives a preliminary no to Avastin for bowel cancer
This article was originally published in Scrip
Executive Summary
NICE, the health technology appraisal body for England and Wales, has given a preliminary no to funding Roche's Avastin (bevacizumab) for NHS patients with advanced bowel cancer. However, the firm says it hopes to change the institute's mind.